

https://dspace.org/

Systhesis and characterization of analogues of the antimalaria alkaloid febrifugine

Pienaar, Daniel Petzer

2006-11-15T12:35:30Z
http://hdl.handle.net/10539/1743

Downloaded from a DSpace repository. https://dspace.org/

Synthesis and characterization of analogues of the antimalarial alkaloid febrifugine

Daniel Petzer Pienaar

A thesis submitted to the Faculty of Science,
University of the Witwatersrand,
Johannesburg,
in fulfilment of the requirements for the degree of
Doctor of Philosophy

July 2005

DECLARATION

I declare that this thesis is my own, unaided work. It is being submitted for the degree of Doctor of Philosophy in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination in any other university.

11 July 2005

ABSTRACT

The subject of this thesis is the development of a potentially simple, general and economical synthetic protocol for the potent antimalarial alkaloid febrifugine (**1**) and its analogues. In Chapter 1, the interesting history of **1**, which includes a description of several reported total syntheses of **1**, is discussed. Natural products derived from **1**, as well as promising synthetic derivatives that display good antimalarial activity, are also discussed. The structure-activity relationships determined to date for **1** and its derivatives are presented in order to substantiate the need for the development of new synthetic strategies towards derivatives of **1** and its 3″-unsubstituted analogue, (±)-deoxyfebrifugine (**14**).

A brief overview of the general strategies used in the Organic Chemistry Group at the University of the Witwatersrand for the synthesis of alkaloids is given in Chapter 2. The Eschenmoser sulfide contraction reaction between a thiolactam and an α-bromocarbonyl compound results in the formation of a vinylogous amide (or "enaminone") product, which can be further manipulated to produce commonly encountered alkaloidal molecular skeletons. The chosen approach to **1** is based on reaction between the pivotal bromide 3-(3-bromo-2-oxopropyl)quinazolin-4(3*H*)-one (**105**) and suitable 3-substituted piperidine-2-thiones.

A series of model studies, described in Chapter 3, was performed in order to test the feasibility of the synthetic strategy. These studies resulted in a new preparation of the key bromide **105** and a new and efficient synthesis of (±)-deoxyfebrifugine (**14**). Enaminone analogues derived from five-, seven-, eight-, nine- and thirteen-membered thiolactams were also prepared for comparison. An interesting difference in the sensitivity of the five- and six-membered model cyclic vinylogous amides towards reducing agents was observed. Whereas three piperidine analogues of **14** could be prepared in high yields by the chemoselective hydrogenation of six-membered cyclic vinylogous amide precursors, the five-membered analogues either reacted non-selectively under various standard hydrogenation conditions, or resisted reduction entirely.

An extension of the approach towards the synthesis of a 3″-amino analogue of febrifugine (**1**) from L-ornithine is discussed in Chapter 4. Several 3-aminated piperidin-2-ones and thiones were prepared, but the subsequent enaminones were stable and characterizable only when the piperidinylidene ring nitrogen was alkylated. However, chemoselective reduction of the enaminone C=C bond in 3-{(*E*)-3-[(3*S*)-3-(*tert*-butoxycarbonylamino)-1-(4-methoxybenzyl)piperidin-2-ylidene]-2-oxopropyl}-quinazolin-4(3*H*)-one (**221**), an interesting 3-acylamino dehydro analogue of **1**, did not give the desired azafebrifugine, but instead yielded a 5,6,7,8-tetrahydro-1*H*-pyrido[3,2-*c*][1,2]oxazine derivative.

Several approaches to febrifugine (**1**) itself based on the successful model studies are discussed in Chapter 5. Initially, stereoselective α-bromination and subsequent substitution by oxygen of piperidin-2-ones derived from the chiral auxiliary (*S*)-phenylglycinol was explored. Unexpected racemization occurred at the α-position of the lactam during this route. A second approach to 3-hydroxypiperidin-2-one from L-arginine was also problematic. Finally, the utility of α-hydroxylation methodology (including Davis methodology) on *N*-substituted piperidin-2-ones was explored. This route yielded a range of 3-oxygenated lactams and thiolactams, many of which displayed optical activity. The crystal structures of several 3-substituted thiolactams were determined and compared. However, attempts to apply the sulfide contraction procedure to these precursors were unsuccessful.

Some investigations designed to explore the structural differences between vinylogous amides derived from the quinazoline-containing bromide **105** and thiolactams of different ring sizes are discussed in Chapter 6. Single crystal X-ray diffraction and NMR spectral data are compared for this series of compounds, the results revealing that the enaminone group in the five-membered ring derivative 3-[(3*Z*)-2-oxo-3-(pyrrolidin-2-ylidene)propyl]quinazolin-4(3*H*)-one **155** possesses a significantly different electronic distribution to the other analogues in the series.

ACKNOWLEDGEMENTS

I wish to express my sincere gratitude to the following people:

My parents Pine and Pettie Pienaar, to whom this thesis is dedicated, for being the outstanding people you are.

My supervisors Prof. Jo Michael and Prof. Charles de Koning, for your support and your patience, and for sharing your expertise with me.

Mr Richard Mampa, Mr Tommie van der Merwe, Mr Manuel Fernandes, Dr Dave Billing, Mr Andreas Lemmerer, Mr Denzel Sannasy, Dr E. Mabel Coyanis, Dr Andy Dinsmore and Dr Riaan Petersen, for their kind assistance and the valuable discussions during this project.

All the postgraduate students in the Organic Chemistry Group at Wits.

My family and friends whose love and support were vital to me whilst pursuing this project.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION TO FEBRIFUGINE

1.1. History of febrifugine 1
1.2. Structural elucidation of febrifugine and isofebrifugine 4
1.3. Other alkaloids related to febrifugine 9
1.4. Antimalarial properties of febrifugine and its derivatives 11
1.5. Published syntheses of febrifugine and isofebrifugine 30
1.6. Published syntheses of (±)-deoxyfebrifugine 41

CHAPTER 2: A PROPOSAL FOR A NEW SYNTHESIS OF FEBRIFUGINE

2.1. Introduction to enaminones and the Wits approach to alkaloid synthesis 47
2.2. Strategy and aims 52

CHAPTER 3: MODEL SYNTHETIC STUDIES

3.1. Aims 57
3.2. Synthesis of quinazolin-4(3*H*)-one 57
3.3. Synthesis of the bromide precursor, 3-(3-bromo-2-oxopropyl)-quinazolin-4(3*H*)-one (**105**) 59
3.4. Synthesis of the thiolactam precursors 62
3.5. The preparation of the model *N*-protected vinylogous amides 70
3.6. The preparation of the model *N*-unprotected vinylogous amides 75
3.7. Deprotection of 3-{(2*E*)-2-[2-oxo-3-(4-oxoquinazolin-3(4*H*)-yl) propylidene]piperidin-1-yl}propanenitrile (**146**) 79
3.8. Chemoselective C=C reduction of the model vinylogous amides 80
3.9. Synthetic studies towards the azetidinylidene enaminone analogue **(183)** 97
3.10. Conclusion and future work 103

CHAPTER 4: APPROACHES TOWARDS THE 3″-AMINO ANALOGUE OF FEBRIFUGINE

4.1. Background 105
4.2. Approach without *N*-protection of the piperidine ring 108
4.3. Approach using *N*-(4-methoxybenzyl) protection 119
4.4. Approach using *N*-(2-methylnaphthyl) protection 125
4.5. Conclusion 127

CHAPTER 5: APPROACHES TOWARDS FEBRIFUGINE

5.1. Approach to febrifugine using a chiral auxiliary; Quirion methodology 128
5.2. Approach to febrifugine from L-arginine 136
5.3. Approaches to febrifugine by α-hydroxylation of piperidin-2-ones 152
5.4. Conclusion 187

CHAPTER 6: THE STRUCTURES OF CYCLIC VINYLOGOUS AMIDES

6.1. Background 188
6.2. Crystal structures of selected model vinylogous amides 198
6.3. Comparison of crystal structures and physical properties 211
6.4. Comparison of torsion angles 215
6.5. Comparison of interatomic distances and bond angles 217
6.6. Comparison of NMR data 222
6.7. Conclusion and future work 226

CHAPTER 7: EXPERIMENTAL SECTION RELATING TO CHAPTER 3

7.1. Synthesis of the bromide precursor, 3-(3-bromo-2-oxopropyl)-quinazolin-4(3*H*)-one (**105**) 230

7.2. Synthesis of the *N*-alkyl thiolactam precursors 232
7.3. Synthesis of the *N*-unprotected thiolactam precursors 236
7.4. Representative procedure for the Eschenmoser sulfur extrusion reaction between pyrrolidyl or piperidyl *N*-alkyl thiolactams and 3-(3-bromo-2-oxopropyl)-4(3*H*)-quinazolinone (**105**) 240
7.5. Representative procedure for the Eschenmoser sulfur extrusion reaction between pyrrolidyl or piperidyl *N*-unprotected thiolactams and 3-(3-bromo-2-oxopropyl)-4(3*H*)-quinazolinone (**105**) 244
7.6. Representative procedure for the chemoselective reduction of the piperidin-2-ylidene *N*-alkyl enaminone products 248
7.7. Chemoselective reduction of **101** 250
7.8. Attempted synthesis of the azetidinylidene enaminone (**183**) 251

CHAPTER 8: EXPERIMENTAL SECTION RELATING TO CHAPTER 4

8.1. Attempts without piperidinyl *N*-protection 255
8.2. Attempts using *N*-(4-methoxybenzyl) as a piperidinyl *N*-protecting group 258
8.3. Attempts using *N*-(2-methylnaphthyl) as a piperidinyl *N*-protecting group 262

CHAPTER 9: EXPERIMENTAL SECTION RELATING TO CHAPTER 5

9.1. Approach to febrifugine using Micouin methodology [i.e. using (*S*)-phenylglycinol as a chiral auxiliary] 266
9.2. Approaches to febrifugine from L-arginine 270
9.3. Approaches to febrifugine using piperidin-2-one α-hydroxylation methodology 274

REFERENCES 289

APPENDICES:

(i) Selected ^{1}H and ^{13}C NMR specra 296
(ii) Compact Disc containing the X-ray crystallography data, the files of which are numbered according to the compound numbers in this thesis

ABBREVIATIONS

Ac	acetyl
aq.	aqueous
Ar	aryl
Bn	benzyl
Boc	*tert*-butoxycarbonyl
Bu and *n*-Bu	butyl
sec-Bu	*sec*-butyl
^{t}Bu	*tert*-butyl
Bz	benzoyl
CAN	ceric ammonium nitrate
cat.	catalytic
CBz	benzyloxycarbonyl
conc.	concentration
m-CPBA	*m*-chloroperoxybenzoic acid
CS	(10-camphorsulfonyl)-oxaziridine
DBU	1,8-diazabicyclo[5.4.0]-undec-7-ene
DCC	dicyclohexylcarbo-diimide
DCCS	(8,8-dichloro-10-camphorsulfonyl)-oxaziridine
DDQ	2,3-dichloro-5,6-dicyano-1,4-benzoquinone
DEPC	diethyl phosphoryl cyanide
DIBAL	diisobutylaluminium hydride
DMAP	4-(*N,N*-dimethylamino)pyridine
DMF	*N,N*-dimethylformamide
DMSO	dimethyl sulfoxide
E2	bimolecular elimination
EC_{50}	50% effective concentration
EI	electron impact
El	electrophile
Et	ethyl
EtOAc	ethyl acetate
EWG	electron withdrawing group
FAB	fast atom bombardment
HMDO	hexamethyldisiloxane
HMDS	1,1,1,3,3,3-hexamethyldisilazane
HPLC	high pressure liquid chromatography
HR	high resolution
IR	infrared
LAH	lithium aluminium hydride
LPS	lipopolysaccharide
Me	methyl
MOM	methoxymethyl
MoOPH	oxodiperoxymolyb-denum(pyridine)(hexa-methylphosphoric

	triamide)
MS	mass spectrometry
Ms	methanesulfonyl
NAP	2-naphthylmethyl
NBS	*N*-bromosuccinimide
l-NMA	*N*-methyl-L-arginine
NOE	Nuclear Overhauser enhancement
Nu	nucleophile
o.n.	overnight
Pd/C	palladium on carbon
Ph	phenyl
PMB	*p*-methoxybenzyl
PPA	polyphosphoric acid
Pr	propyl
^{i}Pr and *i*-Pr	isopropyl
Q	quinazolin-2-yl
rt	room temperature
s.m.	starting material
S_N1	unimolecular nucleophilic substitution
S_N2	bimolecular nucleophilic substitution
TBDMS	*tert*-butyldimethylsilyl
TBDPS	*tert*-butyldiphenylsilyl
TBS	*tert*-butyldimethylsilyl
Tf	trifluoromethane-sulfonyl
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	thin layer chromatography
TMS	trimethylsilyl
Ts	*p*-toluenesulfonyl
UV	ultraviolet